<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04780802</url>
  </required_header>
  <id_info>
    <org_study_id>VIR-20-13</org_study_id>
    <nct_id>NCT04780802</nct_id>
  </id_info>
  <brief_title>Balloon Assisted Transarterial Therapy for Hepatocellular Carcinoma</brief_title>
  <official_title>Balloon Assisted Transarterial Therapy for Hepatocellular Carcinoma: a Study on the Proof of Treatment Concept and Exploration of Selection Criteria for Clinical Application</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese University of Hong Kong</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To prove the treatment concept of the use of balloon assistance in transarterial therapy for&#xD;
      HCC and to explore the selection criteria for clinical application of balloon assistance in&#xD;
      transarterial therapy for HCC.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Transcatheter arterial chemoembolization (TACE) has been playing an important role in the&#xD;
      treatment algorithm for patients with multifocal or large intrahepatic lesions of&#xD;
      hepatocellular carcinoma (HCC) not eligible for surgical resection, transplantation, or local&#xD;
      ablative therapy. The use of balloon assisted TACE has been proposed recently and it could be&#xD;
      one of the possible ways to improve the effectiveness of drug delivery to the target tumor&#xD;
      and therefore leading to improved treatment outcome.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">September 30, 2021</start_date>
  <completion_date type="Anticipated">January 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The change in hemodynamics of arterial blood supply to HCC tumors</measure>
    <time_frame>immediately after completion of procedure</time_frame>
    <description>The change in number of feeding arteries</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The change in the perfusion pattern of HCC tumors</measure>
    <time_frame>immediately after completion of procedure</time_frame>
    <description>The change in perfusion pressure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The degree of completeness of coverage of the tumor vasculature</measure>
    <time_frame>within 30 minutes after completion of procedure</time_frame>
    <description>The degree of completeness of coverage of the tumor vasculature at the completion of the treatment as evaluated on CT scan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor response</measure>
    <time_frame>3 months</time_frame>
    <description>Tumor response by CT such as complete response according to European Association for the Study of the Liver (EASL) necrosis guidelines.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>Ballloon catheter</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Balloon-assisted transarterial therapy will be performed in the first treatment session only</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>The balloon catheter is placed at the various arterial feeders of the tumor</intervention_name>
    <description>use of a balloon catheter for providing balloon occlusion, in addition to the standard microcatheter for drug delivery, both catheters are to be placed in parallel through a single guide catheter. Only one arterial puncture wound is involved. The inflated balloon provides temporary occlusion of all arterial tumor feeders except for the one which is selectively catheterized with a microcatheter for delivery of the therapeutic agent. The therapeutic agent consists of Lipiodol mixed with a chemotherapeutic drug, it is delivered through the microcatheter under fluoroscopic control.</description>
    <arm_group_label>Ballloon catheter</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients of age above 18 years&#xD;
&#xD;
          2. Patients who are indicated for transarterial treatment for HCC&#xD;
&#xD;
          3. Child-Pugh A or B cirrhosis&#xD;
&#xD;
          4. Eastern Cooperative Oncology Group performance score 0 or 1&#xD;
&#xD;
          5. BCLC A or B&#xD;
&#xD;
          6. No previous treatment with liver resection, ablation, chemotherapy, radiotherapy or&#xD;
             transarterial embolization (with or without chemotherapy),&#xD;
&#xD;
          7. HCC diagnosed by typical enhancement patterns on cross sectional imaging or histology.&#xD;
&#xD;
          8. No extra-hepatic involvement on non-enhanced CT thorax and triphasic contrast enhanced&#xD;
             CT abdomen.&#xD;
&#xD;
          9. No invasion of portal vein or hepatic vein&#xD;
&#xD;
         10. Massive expansive tumor morphology with measurable lesion on CT (characterized by&#xD;
             well-defined spherical or globular configuration, with or without tumor capsule or&#xD;
             satellite lesions)&#xD;
&#xD;
         11. Total tumor mass &lt; 50% liver volume&#xD;
&#xD;
         12. Size of any individual tumor &lt;= 7cm in largest dimension&#xD;
&#xD;
         13. Serum creatinine &lt; 130 umol/L or Creatinine clearance &gt; 55 ml/min.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Concurrent ischemic heart disease or heart failure&#xD;
&#xD;
          2. History of asthma, chronic obstructive airway disease or respiratory decompensation.&#xD;
&#xD;
          3. History of acute tumor rupture presenting with hemo-peritoneum&#xD;
&#xD;
          4. Biliary obstruction not amenable to percutaneous or endoscopic drainage&#xD;
&#xD;
          5. Child-Pugh C cirrhosis&#xD;
&#xD;
          6. History of hepatic encephalopathy&#xD;
&#xD;
          7. Intractable ascites not controllable by medical therapy&#xD;
&#xD;
          8. History of variceal bleeding within last 3 months&#xD;
&#xD;
          9. Serum total bilirubin level &gt; 50 umol/L&#xD;
&#xD;
         10. Serum albumin level &lt; 26 g/L&#xD;
&#xD;
         11. INR &gt; 1.3&#xD;
&#xD;
         12. Infiltrative tumor morphology (characterized by ill- defined tumor margin and&#xD;
             amorphous configuration) or diffuse tumor morphology (characterized by large number of&#xD;
             small nodules)&#xD;
&#xD;
         13. Arterio-portal venous shunt affecting &gt;1 hepatic segment on CT&#xD;
&#xD;
         14. Arterial-hepatic venous shunt with hepatic vein opacified in arterial phase on CT&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Simon Yu, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>DIIR, CUHK, Hong Kong</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Imaging and Interventional Radiology, Prince of Wales Hospital, The Chinese University of Hong Kong</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carmen Wong</last_name>
      <phone>(852)3505 3210</phone>
      <email>carmenwongsp@cuhk.edu.hk</email>
    </contact>
    <contact_backup>
      <last_name>Pui Man Chong</last_name>
      <phone>(852)3505 4094</phone>
      <email>siuman@cuhk.edu.hk</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Hong Kong</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 30, 2020</study_first_submitted>
  <study_first_submitted_qc>March 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 4, 2021</study_first_posted>
  <last_update_submitted>August 2, 2021</last_update_submitted>
  <last_update_submitted_qc>August 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese University of Hong Kong</investigator_affiliation>
    <investigator_full_name>Simon Yu</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

